BioWorld

June 26, 2002

BioCryst Reports Lead Flu Drug Fails In Phase III Against Placebo

BioCryst Pharmaceuticals Inc. stopped development of its lead drug candidate, peramivir, on poor preliminary data from a Phase III influenza study. (BioWorld Today) Read More

Celera Diagnostics, Abbott Align For In Vitro Molecular Diagnostics

Key To Hair Loss In Mouse, Man Traced To Key Keratin 17 Mutant Via Two Exotic Follicle Disorders

Geron Restructuring Leaves Focus On Product Development

Other News To Note

Odyssey Raises $15M In Series B To Fund Work In Drug Discovery

Today's news in brief

BioWorld

IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

BioWorld Science

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...

Illustration of head with maze that is missing parts

Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke

BioWorld Science

Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...

New mechanism of action identified for QC-6352

BioWorld Science

QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...

VST Bio’s VB-001 is neuroprotector after stroke

BioWorld Science

At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...